GSK is set to buy IDRx, a US cancer drug company, for up to $1.15 billion to enhance its oncology portfolio and address treatment gaps. GSK to Acquire US Cancer Drug Firm IDRx for Up to $1.15 Billion Plymouth: GSK, the UK’s second-largest drugmaker, is making a big move by acquiring IDRx, a company focused…
GSK is set to buy IDRx, a US firm focused on rare cancer therapies, for up to £1bn, aiming to enhance treatment options. GSK Acquires US Rare Cancer Treatment Developer for Up to £1bn Boston: GSK is making a big move by buying IDRx, a biopharmaceutical company in the US. They’re paying up to $1.15…
Sage Therapeutics focuses on brain health medicines, including treatments for depression and essential tremors, with ongoing clinical trials. Sage Therapeutics, Inc. Stock News and Insights on Yahoo Finance Cambridge: So, Sage Therapeutics is making waves in the biopharmaceutical world. They’re all about brain health and have some cool products in the pipeline. One of their…
